Page last updated: 2024-12-06
moprolol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
moprolol: (-)-moprolol is beta-blocker & anti-hypertensive agent; (+)-moprolol is inactive; SD 1601 refers to HCl; RN given refers to parent cpd without isomeric designation; structure in Negwer, 5th ed, #6316 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71213 |
| CHEMBL ID | 156901 |
| CHEBI ID | 134974 |
| SCHEMBL ID | 80724 |
| MeSH ID | M0055137 |
Synonyms (37)
| Synonym |
|---|
| (+-)-moprolol |
| moprolol |
| CHEBI:134974 |
| CHEMBL156901 |
| 1-(2-methoxyphenoxy)-3-(propan-2-ylamino)propan-2-ol |
| AKOS005254328 |
| 5741-22-0 |
| dl-moprolol |
| moprololum [inn-latin] |
| moprololum |
| a94hch4225 , |
| 1-(isopropylamino)-3-(o-methoxyphenoxy)-2-propanol |
| einecs 227-254-7 |
| unii-a94hch4225 |
| moprolol [inn] |
| 1-(2-methoxyphenoxy)-3-((1-methylethyl)amino)-2-propanol |
| [2-hydroxy-3-(2-methoxyphenoxy)propyl](propan-2-yl)amine |
| moprolol [who-dd] |
| moprolol [mi] |
| SCHEMBL80724 |
| MLS006011700 |
| smr004703428 |
| (+/-)-moprolol |
| LFTFGCDECFPSQD-UHFFFAOYSA-N |
| 1-(isopropylamino)-3-(2-methoxyphenoxy)propan-2-ol |
| STL488508 |
| 2-propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]- |
| Q15634009 |
| DTXSID00863612 |
| BRD-A51747092-003-01-4 |
| BBL100082 |
| mfcd00864582 |
| (+/-)-moprolol; dl-moprolol |
| ()-moprolol; dl-moprolol |
| 1-(2-methoxyphenoxy)-3-[(propan-2-yl)amino]propan-2-ol |
| CS-0028195 |
| HY-108306 |
Research Excerpts
Overview
Levomoprolol is a beta-blocking agent used in the topical treatment of glaucoma.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Levomoprolol is a beta-blocking agent used in the topical treatment of glaucoma. " | ( Determination by coupled high-performance liquid chromatography-gas chromatography of the beta-blocker levomoprolol in plasma following ophthalmic administration. Brenn, E; Figini, G; Gazzaniga, A; Gianesello, V, 1989) | 1.05 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| methoxybenzenes | Any aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (64.29) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 123.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (123.42) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (17.65%) | 5.53% |
| Reviews | 1 (5.88%) | 6.00% |
| Case Studies | 1 (5.88%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (70.59%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||